For Immediate Release: April 20, 2015
Medpace Associate Director, Recruiting & Community Affairs, Mark Metzner and MARC’s Dr. Charles Pierce to speak at the Association of Clinical Research Professionals (ACRP), April 26th, on Best Practices in Patient Recruitment.
CINCINNATI, OH — (April 20, 2015) – Medpace’s Mark Metzner and Dr. Charles Pierce will present at the ACRP annual conference on the topic, “The 10 Reasons Your Recruiting Department is the Key to Your Success.” The sessions will take place at 8:30 am-10:30 am PCT. The presentation will provide best practices in successful subject recruitment.
Medpace, a leader in conducting physician led, global, full-service clinical studies, is home to a Cincinnati -based, 96 bed clinical pharmacology unit. Medpace CPU is adept at recruiting both normal healthy and specialty populations for sponsors need over a variety of therapeutic areas, metabolic, cardiovascular, and rheumatoid arthritis studies.
Medpace is actively involved in patient recruitment and supports that effort through a new initiative. Medpace CPU has established a “Physician Outreach” program to facilitate recruitment of specific patient populations. The program is administrated by the CPU recruitment department, and features an Outreach Coordinator and special population recruiter. Medpace continues to support these efforts at a high level with a state of the art call center and innovative media tactics.
ABOUT MEDPACE CLINICAL PHARMACOLOGY UNIT (CPU)
The Medpace Clinical Pharmacology Unit (CPU) is dedicated to the conduct of early-phase clinical pharmacology studies in normal healthy volunteers, special populations, and patient populations over a spectrum of diseases including cardiovascular and metabolic diseases. Medpace CPU is a fully owned subsidiary of Medpace, Inc. An expanded state-of-the-art facility opened in July 2012 on the Medpace clinical research campus which is centrally located in Cincinnati, Ohio, approximately 20 miles from the Greater Cincinnati / Northern Kentucky International Airport. As a full-service CRO, Medpace offers a suite of Phase I services through its CPU, Bioanalytical lab, consulting, and regulatory capabilities. The Medpace investment in early phase research involves cutting edge technology, instrumentation, and process, developed by 20 years in clinical research, led by therapeutic experts.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and rare and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 1800 employees and has clinical trial experience in over 47 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly owned business units to provide cohesive, streamlined, and standardized trial management. For more information visit the Medpace website at www.medpace.com